Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   University of Washington;   National Cancer Institute (NCI)Active, not re...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast CancerInterventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysisSponsors:   University of Washington;   National Cancer Institute (NCI)Active, not re...
Source: ClinicalTrials.gov - October 31, 2012 Category: Research Source Type: clinical trials

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition:   Breast CancerInterventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placeboSponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)Recruiting - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 24, 2012 Category: Research Source Type: clinical trials

Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer
Condition:   High Risk Prostate CancerIntervention:   Radiation: IMRT TechniqueSponsor:   Sergio FariaRecruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2012 Category: Research Source Type: clinical trials

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate CancerInterventions:   Biological: bevacizumab;   Other: laboratory biomarker analysisSponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   GenentechCompleted - verified July 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 30, 2012 Category: Research Source Type: clinical trials

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate CancerInterventions:   Biological: bevacizumab;   Other: laboratory biomarker analysisSponsors:   Barbara Ann Karmanos Cancer Institute;   Genentech, Inc.Completed - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 30, 2012 Category: Research Source Type: clinical trials

S1202: Duloxetine Hydrochloride to Treat Muscle, Bone, and Joint Pain in Pts W/Early-Stage Breast Cancer Receiving Hormone Therapy
Conditions:   Breast Cancer;   Musculoskeletal Complications;   PainInterventions:   Drug: duloxetine hydrochloride;   Other: placeboSponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)Recruiting - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 11, 2012 Category: Research Source Type: clinical trials

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Condition:   Prostate CancerInterventions:   Drug: TAP-144-SR(6M);   Drug: TAP-144-SR(3M)Sponsor:   TakedaCompleted - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2012 Category: Research Source Type: clinical trials

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelinSponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   NRG OncologyActive, not recruiting - verified May 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 3, 2012 Category: Research Source Type: clinical trials

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Condition:   Prostate CancerInterventions:   Drug: TAP-144-SR(6M);   Drug: TAP-144-SR(3M)Sponsor:   TakedaCompleted - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2012 Category: Research Source Type: clinical trials

A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Condition:   Premenopausal Breast CancerInterventions:   Drug: TAP-144-SR(6M);   Drug: TAP-144-SR(3M)Sponsor:   TakedaCompleted - verified February 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2012 Category: Research Source Type: clinical trials